CP Group has acquired 15% stake in Sinovac Life Sciences, a leading Chinese vaccine developer, with a total investment value of 15.4 billion baht.
CP Group, through its subsidiary in Hongkong and operated by CP Pharmaceutical Group, has investe 515 million US dollars (approx. 15,450 million baht) to acquire 15% stake of Sinovac Life Sciences, which is a Chinese vaccine developer responsible for the development of CoronaVac under Sinovac Biotech.
Yesterday, the Thai Prime Minister Prayut Chan-o-cha stated that the government is expecting to import 2 million doses of China’s coronavirus vaccine developed by Sinovac Biotech for healthcare workers, while waiting for 26 million doses from AstraZeneca.
Thailand’s Centre for Covid-19 Situation Administration (CCSA) stated that it is expecting the first batch of 200,000 doses from Sinovac to be available next month, providing that the vaccine is approved by Thailand and China’s FDA.